A
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Supports a bullish reading. Current ratio 1.96 · operating margin 21%
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
VENTE TOTALE: 634 titres (~95 971,75 $ US)
- Insiders
- Dolsten Mikael
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$95,972
Avg sell (VWAP, 90d window) $151.38 vs last close —
- Last activity
- 2026-09-04
- Last synced
-
2026-09-10 10:26:50
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-04 | Dolsten Mikael | Sell | 634 | $151.38 | $95,972 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-09-09
Despite a solid balance sheet (liquidity score: 75), the weak catalyst score (25) with no meaningful event-driven trigger (NONE type) and mixed insider activity significantly limit the near-term upside thesis.
The first sentence of the analysis written for A on 2026-09-09 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 52.4% | 54.3% | 50.7% | 54.4% | 53.9% | |
| Ebit Margin | 22.3% | 24.8% | 21.0% | 23.2% | 22.8% | |
| Ebitda Margin | 26.4% | 28.8% | 24.9% | 27.8% | 27.9% | |
| Operating Profit Margin | 21.3% | 22.9% | 19.8% | 23.6% | 21.3% | |
| Pretax Profit Margin | 20.7% | 23.4% | 19.6% | 22.0% | 21.5% | |
| Continuous Operations Profit Margin | 18.8% | 19.8% | 18.1% | 18.3% | 19.1% | |
| Net Profit Margin | 18.8% | 19.8% | 18.1% | 18.3% | 19.1% | |
| Bottom Line Profit Margin | 18.8% | 19.8% | 18.1% | 18.3% | 19.1% | |
| Current Ratio | 1.957 | 2.089 | 2.611 | 2.030 | 2.224 | |
| Quick Ratio | 1.521 | 1.566 | 1.968 | 1.472 | 1.738 | |
| Solvency Ratio | 0.266 | 0.260 | 0.307 | 0.301 | 0.288 | |
| Cash Ratio | 0.762 | 0.701 | 0.992 | 0.566 | 0.869 | |
| Price To Earnings Ratio | 31.887 | 29.349 | 24.495 | 33.019 | 39.462 | |
| Price To Earnings Growth Ratio | 9.438 | 5.630 | 34.212 | 6.258 | 0.557 | |
| Forward Price To Earnings Growth Ratio | 9.438 | 5.630 | 34.212 | 6.258 | 0.557 | |
| Price To Earnings Diluted Ratio | 32.026 | 29.415 | 24.671 | 33.098 | 39.863 | |
| Price To Earnings Diluted Growth Ratio | 10.134 | 5.135 | 103.123 | 5.434 | 0.559 | |
| Price To Book Ratio | 6.144 | 6.407 | 5.199 | 7.798 | 8.860 | |
| Price To Sales Ratio | 5.961 | 5.805 | 4.448 | 6.041 | 7.556 | |
| Price To Free Cash Flow Ratio | 35.955 | 27.524 | 20.618 | 40.516 | 36.841 | |
| Price To Operating Cash Flow Ratio | 26.568 | 21.582 | 17.151 | 31.529 | 32.152 | |
| Debt To Assets Ratio | 0.264 | 0.302 | 0.254 | 0.263 | 0.255 | |
| Debt To Equity Ratio | 0.498 | 0.606 | 0.468 | 0.522 | 0.506 | |
| Debt To Capital Ratio | 0.332 | 0.377 | 0.319 | 0.343 | 0.336 | |
| Long Term Debt To Capital Ratio | 0.312 | 0.362 | 0.319 | 0.340 | 0.336 | |
| Financial Leverage Ratio | 1.888 | 2.008 | 1.841 | 1.985 | 1.986 | |
| Working Capital Turnover Ratio | 3.223 | 2.802 | 3.037 | 3.417 | 3.129 | |
| Operating Cash Flow Ratio | 0.664 | 0.924 | 1.105 | 0.705 | 0.869 | |
| Operating Cash Flow Sales Ratio | 0.224 | 0.269 | 0.259 | 0.192 | 0.235 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.739 | 0.784 | 0.832 | 0.778 | 0.873 | |
| Debt Service Coverage Ratio | 4.094 | 11.645 | 16.884 | 13.792 | 19.901 | |
| Interest Coverage Ratio | 13.205 | 15.500 | 14.211 | 19.262 | 16.630 | |
| Short Term Operating Cash Flow Coverage Ratio | 5.128 | 38.911 | 0.000 | 36.444 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.465 | 0.490 | 0.648 | 0.474 | 0.544 | |
| Capital Expenditure Coverage Ratio | 3.830 | 4.632 | 5.946 | 4.509 | 7.857 | |
| Dividend Paid And Capex Coverage Ratio | 2.263 | 2.686 | 3.147 | 2.425 | 3.494 | |
| Dividend Payout Ratio | 0.216 | 0.213 | 0.214 | 0.199 | 0.195 | |
| Enterprise Value Multiple | 23.425 | 21.363 | 18.518 | 22.616 | 27.804 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 52.4% | ▼-1.9% | ▼-0.7% |
| Ebit Margin | 22.3% | ▼-2.6% | ▼-0.5% |
| Ebitda Margin | 26.4% | ▼-2.4% | ▼-0.8% |
| Operating Profit Margin | 21.3% | ▼-1.6% | ▼-0.5% |
| Pretax Profit Margin | 20.6% | ▼-2.7% | ▼-0.8% |
| Continuous Operations Profit Margin | 18.8% | ▼-1.1% | ▼-0.1% |
| Net Profit Margin | 18.8% | ▼-1.1% | ▼-0.1% |
| Bottom Line Profit Margin | 18.8% | ▼-1.1% | ▼-0.1% |
| Current Ratio | 1.957 | ▼-0.132 | ▼-0.225 |
| Quick Ratio | 1.521 | ▼-0.046 | ▼-0.133 |
| Solvency Ratio | 0.266 | ▲0.006 | ▼-0.018 |
| Cash Ratio | 0.762 | ▲0.061 | ▼-0.016 |
| Price To Earnings Ratio | 31.887 | ▲2.538 | ▲0.244 |
| Price To Earnings Growth Ratio | 9.438 | ▲3.809 | ▼-1.780 |
| Forward Price To Earnings Growth Ratio | 9.438 | ▲3.809 | ▼-1.780 |
| Price To Earnings Diluted Ratio | 32.026 | ▲2.611 | ▲0.212 |
| Price To Earnings Diluted Growth Ratio | 10.134 | ▲4.999 | ▼-14.743 |
| Price To Book Ratio | 6.144 | ▼-0.263 | ▼-0.737 |
| Price To Sales Ratio | 5.961 | ▲0.157 | ▼-0.001 |
| Price To Free Cash Flow Ratio | 35.955 | ▲8.431 | ▲3.664 |
| Price To Operating Cash Flow Ratio | 26.568 | ▲4.986 | ▲0.772 |
| Debt To Assets Ratio | 0.264 | ▼-0.038 | ▼-0.004 |
| Debt To Equity Ratio | 0.498 | ▼-0.108 | ▼-0.022 |
| Debt To Capital Ratio | 0.332 | ▼-0.045 | ▼-0.009 |
| Long Term Debt To Capital Ratio | 0.311 | ▼-0.050 | ▼-0.022 |
| Financial Leverage Ratio | 1.888 | ▼-0.120 | ▼-0.054 |
| Working Capital Turnover Ratio | 3.223 | ▲0.422 | ▲0.102 |
| Operating Cash Flow Ratio | 0.664 | ▼-0.260 | ▼-0.189 |
| Operating Cash Flow Sales Ratio | 0.224 | ▼-0.045 | ▼-0.011 |
| Free Cash Flow Operating Cash Flow Ratio | 0.739 | ▼-0.045 | ▼-0.062 |
| Debt Service Coverage Ratio | 4.094 | ▼-7.552 | ▼-9.169 |
| Interest Coverage Ratio | 13.205 | ▼-2.295 | ▼-2.556 |
| Short Term Operating Cash Flow Coverage Ratio | 5.128 | ▼-33.783 | ▼-10.969 |
| Operating Cash Flow Coverage Ratio | 0.465 | ▼-0.025 | ▼-0.059 |
| Capital Expenditure Coverage Ratio | 3.830 | ▼-0.802 | ▼-1.524 |
| Dividend Paid And Capex Coverage Ratio | 2.263 | ▼-0.423 | ▼-0.540 |
| Dividend Payout Ratio | 0.216 | ▲0.004 | ▲0.009 |
| Enterprise Value Multiple | 23.425 | ▲2.062 | ▲0.680 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $41.42B | $37.79B | $30.39B | $41.37B | $47.75B | |
| Enterprise value | $42.98B | $40.03B | $31.54B | $43.08B | $48.99B | |
| EV / Sales | 6.19x | 6.15x | 4.62x | 6.29x | 7.75x | |
| EV / Op. cash flow | 27.57x | 22.86x | 17.80x | 32.84x | 32.99x | |
| EV / Free cash flow | 37.31x | 29.16x | 21.39x | 42.20x | 37.80x | |
| EV / EBITDA | 23.43x | 21.36x | 18.52x | 22.62x | 27.80x | |
| Net debt / EBITDA | 0.85x | 1.20x | 0.67x | 0.90x | 0.71x | |
| Current ratio | 1.96x | 2.09x | 2.61x | 2.03x | 2.22x | |
| Income quality | 3.59x | 1.36x | 1.43x | 1.05x | 1.23x | |
| Graham number | $50 | $45 | $43 | $41 | $40 | |
| Graham net-net | -$9 | -$11 | -$6 | -$9 | -$8 | |
| Tax burden | 90.8% | 84.7% | 92.6% | 83.4% | 89.0% | |
| Interest burden | 92.8% | 94.1% | 93.4% | 94.7% | 94.4% | |
| Working capital | $2.25B | $2.06B | $2.58B | $1.92B | $2.09B | |
| Invested capital | $9.19B | $9.04B | $8.44B | $7.79B | $7.99B | |
| Return on assets | 10.2% | 10.9% | 11.5% | 11.9% | 11.3% | |
| Operating ROA | 12.0% | 13.2% | 12.7% | 15.2% | 13.3% | |
| Return on tangible assets | 16.7% | 18.9% | 19.6% | 21.8% | 21.0% | |
| Return on equity | 19.3% | 21.9% | 21.2% | 23.6% | 22.5% | |
| Return on invested capital | 12.6% | 12.6% | 13.6% | 15.5% | 13.3% | |
| Return on capital employed | 14.2% | 15.0% | 14.7% | 18.7% | 15.0% | |
| Earnings yield | 3.1% | 3.4% | 4.1% | 3.0% | 2.5% | |
| Free cash flow yield | 2.8% | 3.6% | 4.9% | 2.5% | 2.7% | |
| Capex / Op. cash flow | 26.1% | 21.6% | 16.8% | 22.2% | 12.7% | |
| Capex / Depreciation | 141.3% | 147.1% | 110.0% | 91.8% | 58.9% | |
| Capex / Sales | 5.9% | 5.8% | 4.4% | 4.2% | 3.0% | |
| SG&A / Sales | 24.6% | 23.3% | 23.9% | 23.9% | 25.6% | |
| R&D / Sales | 6.5% | 7.4% | 7.0% | 6.8% | 7.0% | |
| Stock comp / Sales | 1.8% | 2.0% | 1.6% | 1.8% | 1.7% | |
| Intangibles / Total assets | 38.6% | 42.4% | 41.2% | 45.3% | 46.3% | |
| Days sales outstanding | 78d | 74d | 69d | 75d | 68d | |
| Days payables outstanding | 63d | 66d | 45d | 68d | 56d | |
| Operating cycle | 191d | 196d | 181d | 196d | 172d | |
| Cash conversion cycle | 128d | 130d | 135d | 128d | 116d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+9.6%EV / Sales ▲+0.6%EV / EBITDA ▲+9.7%EV / Op. cash flow ▲+4.708Earnings yield ▼-0.003Graham number ▲+4.576
Profitability
Return on equity ▼-0.025Return on assets ▼-0.006Return on invested capital +0.000Return on capital employed ▼-0.007Operating ROA ▼-0.011Income quality ▲+2.234Tax burden ▲+0.061
Efficiency
Days sales outstanding ▲+3.883Days payables outstanding ▼-3.302Operating cycle ▼-4.502Cash conversion cycle ▼-1.200Capex / Sales ▲+0.001R&D / Sales ▼-0.008
Balance-sheet strength
Current ratio ▼-0.132Net debt / EBITDA ▼-0.345Working capital ▲+183000000.000Invested capital ▲+145000000.000Intangibles / Total assets ▼-0.038
Change over 5 years
Valuation
Market cap ▼-13.2%EV / Sales ▼-20.2%EV / EBITDA ▼-15.8%EV / Op. cash flow ▼-5.419Earnings yield ▲+0.006Graham number ▲+9.831
Profitability
Return on equity ▼-0.031Return on assets ▼-0.011Return on invested capital ▼-0.008Return on capital employed ▼-0.007Operating ROA ▼-0.012Income quality ▲+2.365Tax burden ▲+0.018
Efficiency
Days sales outstanding ▲+10.419Days payables outstanding ▲+7.047Operating cycle ▲+19.584Cash conversion cycle ▲+12.537Capex / Sales ▲+0.029R&D / Sales ▼-0.004
Balance-sheet strength
Current ratio ▼-0.267Net debt / EBITDA ▲+0.146Working capital ▲+156000000.000Invested capital ▲+1196000000.000Intangibles / Total assets ▼-0.077
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2025-09-23 | Julie Johnson | Buy | $1,001 - $15,000 | Filing |
| 2025-09-23 | Julie Johnson | Buy | $1,001 - $15,000 | Filing |
| 2025-09-22 | Julie Johnson | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-01-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-09-22 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-09-22 | Julie Johnson | Purchase | $1,001 - $15,000 |
| 2025-07-15 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-06-16 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-05-14 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-05-11 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-04-16 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-04-07 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-03-31 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-03-12 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-03-03 | Julie Johnson | Sale | $1,001 - $15,000 |
| 2024-10-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-06-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-06-16 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-05-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-05-05 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2022-02-17 | Ro Khanna | Purchase | $50,001 - $100,000 |
| 2022-02-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-20 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-11-17 | Peter Welch | Sale (Full) | $1,001 - $15,000 |
| 2021-02-15 | Peter Meijer | Sale (Full) | $1,001 - $15,000 |
| 2020-04-08 | Peter Welch | Sale (Partial) | $1,001 - $15,000 |
| 2019-05-22 | Peter Welch | Purchase | $1,001 - $15,000 |
| 2018-05-15 | Lamar Seeligson Smith | Purchase | $1,001 - $15,000 |
| 2018-04-12 | Lamar Seeligson Smith | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-08 Agilent Announces Retirement of Board Chair Koh Boon Hwee, Appointment of Glenn Boehnlein to Board of Directors SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Koh Boon Hwee, independent chair of the company''s board of directors, retired from the board effective Sept. 4, 2026, following more than two decades of service as a director. Koh joined Agilent''s board in 2003 and served as independent chair from 2017 until his retirement.He chaired the board''s Executive Committee and Nominating and Corporate Governance Committee. Koh brought extensive international l.
- 2026-09-07 Agilent (A) Upgraded to Buy: What Does It Mean for the Stock? Agilent (A) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 2026-09-04 Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the U.S. launch of the Agilent S540MD Slide Scanner System, a whole slide imaging (WSI) digital scanner, following FDA clearance. This launch underscores Agilent''s ongoing commitment to digital pathology, broadening its portfolio to address the increasing demand for high-throughput solutions in clinical laboratories.Pathology laboratories continue to face increasing pressure to improve diagnostic efficiency.
- 2026-09-01 Agilent Introduces the Cary 635 FTIR Spectrometer SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the Agilent Cary 635 FTIR spectrometer, setting a new standard for compact, high-performance Fourier transform infrared (FTIR) analysis. Combining robust engineering, superior performance, and intuitive usability, the Cary 635 FTIR provides laboratories with a powerful solution that enhances reliability, boosts productivity, and delivers the versatility required for today''s analytical challe.
- 2026-09-01 INTURAI VENTURES COMPLETES DOMECOMMAND ACQUISITION INTURAI VENTURES COMPLETES DOMECOMMAND ACQUISITION PR Newswire VANCOUVER, BC, Sept. 1, 2026
- 2026-08-31 International Markets and Agilent (A): A Deep Dive for Investors Explore how Agilent''s (A) revenue from international markets is changing and the resulting impact on Wall Street''s predictions and the stock''s prospects.
- 2026-08-27 Agilent Technologies: Q3 Growth, Expanding Margins, And Raised Guidance Agilent Technologies is upgraded to Buy after a strong Q3 2026, with revenue up 8% and EPS up 18% YoY. All three segments posted robust growth, notably Life Sciences and Diagnostics, which saw operating margin jump nearly 600 bps to 23.5%. Guidance for Q4 and FY26 implies continued momentum, with management projecting 6.5–7.5% revenue growth and 8.5% EPS growth for Q4.
- 2026-08-26 Agilent Technologies, Inc. (A) Q3 2026 Earnings Call Transcript Agilent Technologies, Inc. (A) Q3 2026 Earnings Call Transcript
- 2026-08-26 Agilent Technologies Q3 Earnings Call Highlights Agilent Technologies NYSE: A reported third-quarter fiscal 2026 revenue of $1.88 billion, with core revenue growth of 7.3%, exceeding the high end of its guidance range. The company said earnings per share were $1.56 excluding tariff-refund benefits, up 14% from a year earlier and $0.06 above the top of its guided range.
- 2026-08-26 Agilent (A) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Agilent (A) give insight into how the company performed in the quarter ended July 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.